following a full submission:
bevacizumab (Avastin®) is not recommended for use within NHS Scotland.
Indication under review: Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelian ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
A randomised double-blind, placebo-controlled, phase III study demonstrated a significant improvement in progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (ROC) treated with bevacizumab in combination with gemcitabine and carboplatin, compared with gemcitabine and carboplatin alone.
The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient to gain acceptance by SMC.
Download detailed advice138KB (PDF)
Medicine details
- Medicine name:
- bevacizumab (Avastin)
- SMC ID:
- 853/13
- Indication:
- Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelian ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 March 2013